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Nina S. Funa1, Kalpana Reddy2, Sulochana Bhandarkar2, Elena V. Kurenova3, Lily Yang4, William G. Cance3,
Michael Welsh1 and Jack L. Arbiser2
The Shb adapter protein is an Src homology 2-domain containing signaling intermediate operating downstream
of several tyrosine kinase receptors, including vascular endothelial growth factor receptor-2. Shb is
multifunctional and apoptosis is one response that Shb regulates. Inhibition of angiogenesis can be used in
cancer therapy, and one way to achieve this is by inducing endothelial cell apoptosis. The angiosarcoma cell line
SVR is of endothelial origin and can be used as a tool for studying in vivo inhibition of angiogenesis, and we
thus employed an Shb-knockdown strategy using an inducible lentiviral system to reduce Shb levels in SVR
cells and to study their responses. Shb knockdown increases the susceptibility of SVR cells to the apoptotic
agents, cisplatin and staurosporine. Simultaneously, Shb knockdown causes reduced focal adhesion kinase
(FAK) activation, monitored as phosphorylation of the regulatory residues tyrosines 576/577. No detectable
effects on Akt or extracellular signal-regulated kinase activity were noted. The altered FAK activity coincided
with an elongated cell phenotype that was particularly noticeable in the presence of staurosporine. In order to
relate the effects of Shb knockdown to in vivo tumorigenicity, cells were exposed to the angiogenesis inhibitor
honokiol, and again the cells with reduced Shb content exhibited increased apoptosis. Tumor growth in vivo
was strongly reduced in the Shb-knockdown cells upon honokiol treatment. It is concluded that Shb regulates
apoptosis and cell shape in tumor endothelial cells via FAK, and that Shb is a potential target for inhibition of
angiogenesis.
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INTRODUCTION
Inhibition of angiogenesis comprises a viable strategy for
cancer treatment. Angiogenesis is a multi-step process
involving endothelial cell proliferation, survival, migration
and altered cell shape and inhibition of any of these
individual components may result in reduced vasculariza-
tion. The angiosarcoma SVR cells are of endothelial origin
and can be employed to screen for inhibitors of angiogenesis.
One compound with antiangiogenic and antitumor properties
is honokiol (Battle et al., 2005; Ishitsuka et al., 2005), which
has been found to cause apoptosis both in vitro and in vivo in
SVR cells and thus can cause tumor reduction upon in vivo
administration. Honokiol was found to inhibit phosphoryl-
ation of vascular endothelial growth factor receptor-2
(VEGFR-2) and block downstream signaling in SVR cells
(Bai et al., 2003).
Shb is an Src homology 2 domain containing adapter
protein operating downstream of several tyrosine kinase
receptors (Anneren et al., 2003). The N-terminus contains
proline-rich motifs, followed by a phosphotyrosine-binding
domain, four putative tyrosine phosphorylation sites and a
C-terminal Src homology 2 domain. The proline-rich motifs
bind SH3 domain proteins such as Src (Anneren et al., 2003)
and c-Abl (Hagerkvist et al., 2007), the phosphotyrosine
binding domain binds focal adhesion kinase (FAK), the
tyrosine phosphorylated residues bind Crk (Anneren et al.,
2003) and c-Abl (Hagerkvist et al., 2007) and the Src
homology 2 domain receptors such as fibroblast growth
factor receptor-1 (Anneren et al., 2003) and VEGFR-2
(Holmqvist et al., 2004). Shb generates signaling complexes
in response to tyrosine kinase receptor activation, and the
biological consequences of these events differ between
different cells. One prominent response to Shb overexpres-
sion is increased apoptosis, which has been observed in
fibroblasts, beta cells and endothelial cells (Anneren et al.,
2003). Particularly, in response to the angiogenesis inhibitors
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angiostatin and endostatin, apoptosis was increased in
Shb-overexpressing endothelial cells (Dixelius et al., 2000).
Although numerous studies have demonstrated apoptosis as a
consequence of Shb overexpression, less is known about the
effects of reduced Shb content on apopotosis. In one recent
study, the Shb content was suppressed by short hairpin RNA
(shRNA)-knockdown in an insulin-producing cell line, and
this caused a reduction in c-Abl activity and cell death upon
exposure to tunicamycin and cisplatin (Siddik 2002; Hagerk-
vist et al., 2007).
To address the role of Shb knockdown on apoptosis in
other cell system, and to relate this to tumor treatment by
inhibition of angiogenesis, we generated SVR cells with
reduced Shb content. We note increased apoptosis in
response to several stress-inducing agents, as well as reduced
FAK activity and altered cell shape. In vivo treatment of Shb-
depleted SVR cells with honokiol potentiated the antitumor
effect and resulted in reduced tumor growth.
RESULTS
Shb knockdown
We have recently described a system for cre-dependent
knockdown of Shb in murine cells (Hagerkvist et al., 2007).
Employing this system on the angiosarcoma cell line, SVR of
endothelial origin yielded efficient Shb knockdown (Figure 1).
The SVR cells were infected with the lentivirus Sico-Shb with
a sequence inserted that produces an shRNA that recognizes
the Shb mRNA upon cre-dependent recombination. These
cells were denoted control, as knockdown had not been
initiated in these. Subsequent infection with adenovirus-cre
induces recombination of the integrated lentivirus and
activation of Shb shRNA (Ventura et al., 2004; Hagerkvist
et al., 2007). This results in a significant reduction of the Shb
protein content (Figure 1a). The Shb protein was tested in a
mass population of adenovirus-cre-treated cells (Shb shRNA)
or in a subclone from the adenovirus-cre-treated cells (Shb
shRNA-1), and both showed a reduced Shb protein content.
Cell death
The cells were used to examine their apoptotic responses to
various stress agents (Figure 1b). The cell death rates of the
three cell lines (control, Shb shRNA, and Shb shRNA-1) were
similar under basal conditions. However, addition of
staurosporine, an agent that induces apoptosis in many cell
types due to serine/threonine kinase inhibition (Kabir et al.,
2002), caused a significant increase in apoptosis of both the
mass population of Shb-knockdown cells (Shb shRNA) and
the knockdown clone (Shb shRNA-1). This increase in
apoptosis was apparent after both 18 and 40 hours exposure
to the drug.
The cells were also exposed to cisplatin, an agent that
causes apoptosis due to DNA damage (Siddik 2002). Both
groups of Shb-knockdown cells exhibited increased apoptosis
after 18 hours exposure to cisplatin (Figure 1b). However, this
difference disappeared at 40 hours, suggesting that loss of Shb
protein accelerates the apoptotic response, but in case
damage is irreparable, apoptosis will eventually ensue.
FAK activity
We decided to search for changes in signaling occurring as a
consequence of Shb knockdown in SVR cells. As Shb has
previously been shown to affect FAK activity (Holmqvist
et al., 2003, 2004), FAK-activity was analyzed in the present
context. A phosphospecific antibody that recognizes phos-
phorylated FAK at tyrosines 576/577 was used to monitor
FAK activity. These phosphorylation sites are present in a
regulatory region of the catalytic domain of FAK and are
thought to reflect activation of FAK kinase (Withers et al.,
1996; Ilic et al., 1998, 2001). Analysis of FAK phosphoryla-
tion at these sites revealed less phosphorylation in the Shb-
knockdown cells, regardless of whether these were main-
tained in 0.1% serum, in 10% serum, or after incubation with
cisplatin (Figure 2a). The level of FAK phosphorylation was
somewhat higher in the presence of 10% serum than in 0.1%
serum, although the reduction induced by Shb knockdown
was still maintained. After exposure to staurosporine, the
most dramatic effect was noted. The combination stauros-
porine and Shb knockdown reduced FAK phosphorylation to
a level that was barely detectable (Figure 2a). It is thus
concluded that Shb regulates FAK activity also in SVR cells.
We also studied Akt and extracellular signal-regulated
kinase (ERK) activity in the Shb-knockdown SVR cells using
phosphospecific antibodies and noted no differences in the
activities of these between the control or the cells with
reduced Shb protein content (Figure 2b). The activity of c-Abl
assessed as phosphorylation of regulatory tyrosines 245 or
418 could not be detected in the SVR cells (results not
shown). We conclude that the main consequences of reduced
Shb content in SVR cells involve FAK signaling.
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Figure 1. Effect of Shb-knockdown on cell death in response to staurosporine
and cisplatin. (a) SVR cells were infected with the lentivirus containing the
Shb shRNA sequence (control, cre ) and subjected to a second infection
with adenovirus containing cre (cre þ ) to initiate Shb knockdown
(Shb shRNA). A subclone from the mass population of Shb shRNA cells was
isolated (Shb shRNA-1, cre þ ). Lysates were prepared and tested for Shb
protein content by Western blotting. ERK is shown as loading control.
(b) Control, Shb shRNA, and Shb shRNA-1 cells were plated and exposed to
1mM staurosporine for the time periods indicated. Percent cell death after
staining for propidium iodide and FACS analysis is shown. n¼ 8. (c) Control,
Shb shRNA, and Shb shRNA-1 cells were plated and exposed to 10mM
cisplatin for the time periods indicated. Percent cell death after staining for
propidium iodide and FACS analysis is shown. n¼ 4. *, **, and *** indicate
Po0.05, 0.01, and 0.001, respectively, when tested against control with
analysis of variance. Means7SEM are given.
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Cell morphology
Altered FAK activity is likely to result in changed cell
morphology (Hong et al., 2003) and thus we studied cell
morphology of control and Shb-knockdown cells by staining the
cytoskeleton with phalloidin (Figure 3). Both populations of
cells with reduced Shb protein content exhibited an elongated
cell shape, regardless of whether the cells were maintained in
10% serum or 0.1% serum. Stress fibers were commonly seen in
all groups of cells, whereas microspikes and membrane ruffles
were uncommon. In the staurosporine-treated cells, the effects
of Shb protein reduction were the most pronounced. The
elongated cell phenotype of these cells became more accen-
tuated by a contraction of the cytoplasm towards the centerline
located at the cellular axis, giving the Shb-knockdown cells a
neurite-like appearance. Blinded scoring of the changes in
Figure 3a was performed and revealed the differences due to
Shb knockdown to be statistically significant (Figure 3b).
Honokiol-induced death is accentuated by reduced Shb protein
As Shb knockdown increased stress-induced apoptosis, we
wanted to investigate the effect of the natural compound
honokiol on apoptosis in these cells (Figure 4). Honokiol is an
antitumor agent that inhibits angiogenesis by interfering with
VEGF signaling (Bai et al., 2003). A part of the honokiol-effect
involves increased apoptosis as detected in SVR cells (Bai
et al., 2003). The rates of cell death were increased in both
groups of cells with reduced Shb protein (Shb shRNA, Shb
shRNA-1) upon exposure to honokiol.
Reduced Shb protein content inhibits in vivo tumor growth in
honokiol-treated mice
To investigate the consequences of Shb knockdown on
in vivo tumor growth of SVR cells, control and Shb-
knockdown cells were injected subcutaneously into nude
mice. The tumor growth without additional treatment was not
affected by reduced Shb protein content (Figure 5a and b). A
low-dose regimen of honokiol administration was provided to
determine whether the increased susceptibility of the Shb-
knockdown cells to honokiol in vitro was conferred to an in
vivo tumor growth situation. The low-dose honokiol admin-
istration protocol did not reduce growth of the control cell
tumors (Figure 5a and b). However, the Shb-knockdown cells
dramatically decreased their tumor growth rate, indicating an
increased susceptibility to the antitumor compound honokiol
upon Shb knockdown (Figure 5c and d). Cell death was
dramatically increased in Shb-knockdown tumors treated
with honokiol (Figure 5d).
DISCUSSION
Treatment of solid tumors still poses a substantial therapeutic
challenge. Other than a few examples (choriocarcinoma,
testicular cancer), solid tumors cannot be eliminated by
chemotherapy alone. Chemotherapeutic agents can cause
tumor cell death through apoptosis, and tumor cells have
developed multiple antiapoptotic defenses, including pro-
teins, which protect against both intrinsic and extrinsic forms
of apoptosis. In addition, proapoptotic genes such as Apaf-1
are silenced through methylation, transcriptional silencing
by Id and polycomb proteins, as well as genetic deletion
(Foreman et al., 1996; Hakem et al., 1998; Pan et al., 1998;
Lyden et al., 1999; Polsky et al., 2001; Wang et al., 2001;
Arbiser 2004; Elstrom et al., 2004; Govindarajan et al., 2005;
Soengas et al., 2006).
Shb is an adapter protein that is associated with numerous
tyrosine kinases, including platelet-derived growth factor
receptor beta, and VEGFR-2 (Anneren et al., 2003; Holmqvist
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Figure 2. Effect of Shb knockdown on FAK, Akt, and ERK activity. (a) Control, Shb shRNA, and Shb shRNA-1 cells were plated and exposed to 0.1%
serum, 10% serum, 0.1% serum plus 1 mM staurosporine, and 0.1% serum plus 10 mM cisplatin for 1 hour. Cells were scraped off the dishes, lysates
prepared that were subjected to Western blot analysis for p576/577 FAK, total FAK, and ERK as loading control. (b) Control, Shb shRNA, and Shb shRNA-1 cells
were plated and exposed to 0.1% serum, 10% serum, 0.1% serum plus 1mM staurosporine, and 0.1% serum plus 10 mM cisplatin for 1 hour. Cells were
scraped off the dishes, lysates prepared that were subjected to Western blot analysis for pAkt, total Akt, pERK, and total ERK. The same blots as in (a) were used.
712 Journal of Investigative Dermatology (2008), Volume 128
NS Funa et al.
SVR Susceptibility to Apoptotic Agents
et al., 2003, 2004). Overexpression of Shb has in many
instances been found to be associated with increased
apoptosis, and with respect to the inhibitors of angiogenesis
angiostatin and endostatin this may involve activation of FAK
(Holmqvist et al., 2003; Hess et al., 2005). FAK is a protein
kinase that is associated with focal adhesions, and mediates
signaling from extracellular matrix proteins and integrins
(Polte et al., 1994; Shattil et al., 1994; Hungerford et al.,
1996; Sieg et al., 1999), thereby being a mediator of crosstalk
between receptor mediated signaling and cues from extra-
cellular matrix. Complete loss of FAK results in embryonic
lethality, but organ-mediated deletion of FAK is compatible
with life when deleted in the skin by cre-mediated
recombination (Ilic et al., 1995; Essayem et al., 2006). FAK
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Figure 3. Effects of Shb knockdown on the cytoskeleton. (a) Control, Shb shRNA, and Shb shRNA-1 cells were cultured on multiwell microscopic slides.
After exposure to 0.1% serum, 10% serum, 0.1% serum plus 1 mM staurosporine, and 0.1% serum plus 10mM cisplatin for 1 hour, the cells were fixed
and stained for phalloidin–rhodamine. Pictures show fluorescence photographs of typical cells from each condition. Original magnification: 400.
(b) Scoring of the elongated phenotype seen in a. Percentage elongated cells (the cell length more than twice the maximum width) are shown. *, **,
and *** indicate Po0.05, 0.01, and 0.001, respectively, when compared with analysis of variance against control. Means7SEM are given for n¼ 8–11.
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Figure 4. Effect of Shb knockdown on honokiol-induced cell death. Control,
Shb shRNA, and Shb shRNA-1 cells were exposed to 10mg/ml honokiol
for 48 hours, after which cell death rates in percent were determined.
* indicates Po0.05 with analysis of variance. Means7SEM are given for n¼ 4.
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is also highly expressed and amplified in human neoplasia,
and is associated with metastatic growth. Interestingly,
expression of a dominant-negative FAK, called FAK-related
non-kinase (FRNK), resulted in decreased metastases, yet had
no effect on primary tumor growth (Hauck et al., 2002). FAK
activation mediates, in part, integrin- and receptor-mediated
activation of phosphoinositol-3 kinase/Akt activation (Schal-
ler et al., 1994; Siesser and Hanks, 2006). Disturbed FAK-
signaling has been shown to cause apoptosis in many
systems, particularly in endothelial cells where numerous
conditions giving rise to apoptosis show reduced FAK
activity, including that of staurosporine treatment (Kabir
et al., 2002; Dai et al., 2004; Kurenova et al., 2004; Ryu
et al., 2006).
In this study, we knocked out Shb in SVR angiosarcoma
cells through a cre-mediated mechanism. This allowed the
examination of the phenotype of Shb knockout without the
potential complicating factor of developmentally mediated
compensation to Shb/FAK blockade. Consistent with prior
data, elimination of Shb led to reduced phosphorylation of
Y576/577 of FAK, thus showing that the blockade of Shb had
a biological effect. SVR cells are driven by functional VEGFR-
2 and oncogenic H-ras. Phenotypically, SVR cells lacking
Shb were elongated with stress fibers and showed increased
sensitivity to apoptotic agents, including cisplatin, stauros-
porine, and honokiol, demonstrating a nonredundant func-
tion of Shb on these parameters. On the other hand, levels of
activated Akt and ERK were not affected. One potential
explanation of this observation is that cells may have several
inputs that give rise to basal expression of Akt and ERK
activation, including oncogenic ras, tyrosine kinase recep-
tors, and extracellular matrix–integrin interactions. Elimina-
tion of Shb–FAK interactions may lead to compensation from
oncogenes or tyrosine kinase receptors in terms of maintain-
ing baseline expression of aberrant signaling, but makes the
resulting tumor cells more dependent, or ‘‘addicted’’ to
signaling from tyrosine kinases and oncogenes and thus its
total survival potential is reduced. The situation in tumors
may differ from primary cells, in which targeted deletion of
FAK in endothelial cells leads to embryonic lethality (Braren
et al., 2006). In these mice, cues from extracellular matrix are
likely required for correct vascular patterning, and cannot be
compensated by other genes.
We decided to test the hypothesis that the total input of
survival signals in Shb-depleted SVR cells is reduced in vivo.
Honokiol is a small molecule that is known to target VEGFR-2,
and was initially discovered to have antiangiogenic activity in
a screen using SVR cells (Bai et al., 2003). If blockade of
Shb–FAK signaling makes tumor cells more dependent on
FAK-independent signaling, one would predict that the cells
would be more sensitive to an agent that targets VEGFR-2.
Loss of Shb had no effect on tumor growth in vivo. We then
tested the effect of a subtherapeutic dose of honokiol on
tumor cells that either possess or lack wild-type Shb.
Treatment of control mice with 40mg/kg honokiol led to an
increase in tumor growth in wild-type SVR cells, but a
significant decrease in tumor volume in Shb knockout mice.
A potential explanation for increased tumor growth in the
low-dose control mice is that blockade of NF-kB signaling in
endothelial cells initially stimulates tumor growth, but
sensitizes endothelial cells to apoptotic stimuli (Kisseleva
et al., 2006). The Shb-knockout cells are more dependent on
VEGFR2 and other compensatory stimuli, and thus are highly
sensitive to honokiol in vivo, leading to decreased tumor
growth.
Our findings have clinical applications. Integrin signaling
has been considered a druggable target, both at the level of
the cell membrane, as well as downstream of the cell surface
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Figure 5. Effect of Shb knockdown on tumor growth in vivo. (a) Nude mice were injected subcutaneously with control or Shb shRNA cells. Tumors after
9 days are shown. (b) Effect of honokiol on tumor growth of control or Shb shRNA cells. Tumors after 9 days are shown. (c) Tumor size of control or
Shb shRNA SVR cells after 9 days with or without honokiol treatment. * indicates Po0.05 with a Students’ t-test when compared against corresponding
control. Means7SEM for n¼ 3. (d) Histologic analysis of tumors: note the massive cell death occurring in the Shb knockout tumor (right) compared
with the control tumor in the presence of honokiol (left).
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integrins. In addition, although endostatin was unsuccessful
in clinical trials as monotherapy, endostatin administration
may select for cells that have decreased Shb expression
(Dixelius et al., 2000; Eder et al., 2002). These resistant cells
may be hypersensitive to agents such as cisplatin or honokiol,
providing a basis for combination or sequential therapy. Our
findings suggest that blockade of Shb–FAK signaling is
unlikely to be effective in patients as monotherapy, yet may
be clinically useful in causing tumors to become dependent
on a more limited repertoire of signaling pathways. Combi-
nation or sequential blockade of Shb–FAK signaling with
tyrosine kinase inhibitors and chemotherapy may prove
beneficial in the treatment of aggressive solid tumors.
MATERIALS AND METHODS
All experiments contained herein were approved by the Emory
University Institutional Review Board.
Shb knockdown
An inducible lentiviral system (Ventura et al., 2004) was used to
reduce the Shb protein content (Hagerkvist et al., 2007) of SVR cells
(Arbiser et al., 1997). SVR cells were infected with the lentivirus
containing the Shb shRNA sequence at 500 multiplicity of infection.
This yielded a cell population with 99% green fluorescent protein-
positivity (indicating lentiviral infection efficiency). The cells were
subjected to a second infection with an adenovirus containing cre-
recombinase Ad-Cre (5 108 PFU/ml) (gift of RS Johnson, UCSD).
This will cause deletion of lentiviral sequences that inhibit
expression of the shRNA and simultaneously delete green fluor-
escent protein. From this population of cells with less than 5%
expressing green fluorescent protein, clones were isolated that
were homogeneously deficient in green fluorescent protein and
thus expressing the Shb shRNA. Consequently, experimentation
was carried out on SVR infected with the shRNA lentivirus
only (control), a mass population of cells subjected to a sequential
adenoviral infection to activate knockdown (Shb shRNA) and
one subclone obtained from the mass population of knockdown
cells (Shb shRNA-1).
Western blot analysis of FAK, Akt, and ERK activity
Cells (control, Shb shRNA, and Shb shRNA-1) were plated at
100,000 in 3 cm tissue culture plates. After 18 hours at 371C, cells
were maintained in 0.1% serum for 4 hours, after which they were
incubated for 1 hour in 10% serum, 1mM staurosporine, 10 mM
cisplatin or maintained in low serum. The cells were washed in
phosphate-buffered saline, scraped off the dishes, collected, and
lysed in SDS-sample buffer. Aliquots were subjected to Western blot
analysis after SDS-PAGE on 7.5% acrylamide gels, probing for
pY576/577-FAK, total FAK, pAkt (S473), total Akt, pERK (T202/
Y204), and total ERK as loading control (antibodies from Cellular
Signaling, Beverly, MA).
Cell death
Cells (control, Shb shRNA, and Shb shRNA-1) were plated at
100,000 in 3 cm diameter tissue culture dishes and maintained for
18 hours at 371C. The cells were then exposed to honokiol (10mg/
ml), staurosporine (1mM), or cisplatin (10 mM) for the time periods
indicated in the figures. Cells were then incubated with 50 mg/ml
propidium iodide for 10minutes, washed with phosphate-buffered
saline, and subjected to flow cytometry to analyze for cell size and
uptake of propidium iodide. Dying cells were smaller than viable
cells with normal or increased propidium iodide uptake.
Cell morphology
Cells (control, Shb shRNA, and Shb shRNA-1) were plated at a
number of 5,000 in each chamber in a six-chamber microscopical
slide. After 18 hours, the serum concentration was reduced to 0.1%.
Following an incubation of an additional 4 hours at 371C, the
chambers were incubated with 10% serum, 1 mM staurosporine,
10 mM cisplatin, or maintained for an additional hour in 0.1% serum.
The glass slides were then washed twice in phosphate-buffered
saline, fixed for 15minutes in 4% paraformaldehyde, washed again
twice in phosphate-buffered saline and permeabilized in 0.1%
Triton-X100 for 10minutes. After additional washing for three times
with phosphate-buffered saline, the cells were blocked with 10%
FBS for 1 hour, washed again and then stained with phalloidin–rho-
damine A (Molecular Probes, Eugene, OR) for 30minutes. After
mounting with anti-fade mounting medium, the morphology was
examined in a Nikon Eclipse TE2000 inverted fluorescence
microscope and photographed. Photographs were scored blindly
for morphology and actin staining.
Tumor growth
One million cells (control and Shb shRNA) were injected sub-
cutaneously into 5-week-old nude mice. For honokiol studies, mice
were treated daily with 40mg/kg honokiol intraperitoneally dis-
solved in 20% Intralipid. Tumor volume was measured with a
Vernier caliper and calculated using the formula (w2 l)0.52, where
w represents the shortest dimension (Arbiser et al., 1997, 2000;
Bai et al., 2003).
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